{"id":2355,"date":"2025-01-08T17:41:32","date_gmt":"2025-01-08T14:41:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2355"},"modified":"2025-03-07T15:26:36","modified_gmt":"2025-03-07T12:26:36","slug":"avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization\/","title":{"rendered":"Avidity Biosciences se prepara para la presentaci\u00f3n y comercializaci\u00f3n de la solicitud de patente b\u00e1sica (BLA) de tres programas de enfermedades musculares raras en 2025"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Avidity Biosciences, Inc., una empresa biofarmac\u00e9utica dedicada al desarrollo de una nueva clase de tratamientos de ARN conocidos como conjugados de oligonucle\u00f3tidos de anticuerpos (AOCsTM), inform\u00f3 hoy sus avances y planes para un a\u00f1o revolucionario en 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Estos importantes hitos esperados incluyen completar tres programas potencialmente de registro, presentar una Solicitud de Licencia Biol\u00f3gica (BLA) para delpacibart zotadirsen (del-zota) para individuos con mutaciones de distrofia muscular de Duchenne susceptibles a la omisi\u00f3n del ex\u00f3n 44 (DMD44), prepararse para varios lanzamientos de productos en DMD44, distrofia miot\u00f3nica tipo 1 (DM1) y distrofia muscular facioescapulohumeral (FSHD), y establecer un negocio internacional completamente integrado para respaldar una l\u00ednea de productos AOC en expansi\u00f3n en cardiolog\u00eda de precisi\u00f3n y enfermedades neuromusculares.<\/p>","protected":false},"excerpt":{"rendered":"<p>A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,128,130,129,66,77],"class_list":["post-2355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-bla","tag-dm1","tag-dmd44","tag-duchenne-muscular-dystrophy","tag-exon-skipping"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2355"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2357"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2355"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}